Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts. Show more

Location: PO Box 30, Winchester, MA, 01890, United States | Website: https://www.synlogictx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

20.01M

52 Wk Range

$0.90 - $1.96

Previous Close

$1.71

Open

$1.71

Volume

19,844

Day Range

$1.63 - $1.75

Enterprise Value

1.145M

Cash

17.03M

Avg Qtr Burn

-804K

Insider Ownership

11.26%

Institutional Own.

64.65%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.